# A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

> **NCT05690945** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 606 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** QL1706
- **DRUG:** Tilesizumab

## Key facts

- **NCT ID:** NCT05690945
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-15
- **Primary completion:** 2029-06
- **Final completion:** 2029-12
- **Target enrollment:** 606 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05690945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05690945, "A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05690945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*